NAD+

Let us settle the most common misunderstanding in the first paragraph: NAD+ (nicotinamide adenine dinucleotide) is not a peptide. It contains no amino acids and no peptide bonds. It is a coenzyme, a small organic molecule that enzymes require in order to function. Its structure is a dinucleotide: a nicotinamide mononucleotide unit joined to an adenosine monophosphate unit through a pyrophosphate bridge. The molecular formula is C₂₁H₂₇N₇O₁₄P₂ and the molecular weight is 663.43 g/mol, which places it far below even the smallest research peptides in structural complexity.

The confusion is understandable. NAD+ vials are sold by the same suppliers that sell research peptides, they arrive as the same lyophilized white powder, they are reconstituted with the same bacteriostatic water, and they are often administered by the same subcutaneous route. None of that changes the chemistry. When you compare NAD+ with an actual peptide such as Epithalon (a four amino acid sequence) or MOTS-c (a sixteen amino acid mitochondrial-derived peptide), you are comparing two entirely different classes of molecule with different synthesis routes, different stability profiles and different biological logic.

NAD+ exists in a redox pair. The oxidized form, written NAD+, accepts a hydride ion and becomes the reduced form, NADH. The cell constantly cycles between the two, and for many metabolic questions the ratio between them matters more than the absolute amount of either. A second phosphorylated pair, NADP+ and NADPH, handles reductive biosynthesis and antioxidant defense. When commercial material is marketed simply as "NAD", it is usually the oxidized NAD+ form.

One structural fact drives almost everything else in this guide. NAD+ is a relatively large, doubly charged molecule at physiological pH. Cell membranes do not welcome it. Mammalian cells are generally understood to build their own NAD+ from smaller precursors rather than importing the intact coenzyme from the bloodstream. That single constraint is why the debate between injection and oral precursors is a real pharmacological question and not a marketing preference.

Educational content only. Nothing here is a recommendation to use NAD+ by any route. Consult a qualified healthcare professional before considering any intervention.

NAD+ has two distinct jobs, and keeping them separate makes the rest of the literature much easier to read.

The first job is redox catalysis. NAD+ is the hydride carrier for central energy metabolism. It accepts electrons during glycolysis, during fatty acid beta-oxidation and at several steps of the tricarboxylic acid cycle, then delivers them to complex I of the mitochondrial electron transport chain, where that energy is eventually converted into ATP. In this role NAD+ is not consumed. It is recycled thousands of times per second, oxidized and reduced in an endless loop. A cell with a collapsed NAD+/NADH ratio cannot sustain oxidative metabolism, which is why the coenzyme is described as central to energy metabolism.

The second job is the one that made NAD+ interesting to aging research. A family of enzymes uses NAD+ as a consumable substrate, cleaving it and releasing nicotinamide as a byproduct. The sirtuins (SIRT1 through SIRT7) are NAD+-dependent deacylases that remove acetyl and other acyl groups from histones and from metabolic enzymes, linking the cell's energy state to gene expression and mitochondrial regulation. The PARP enzymes, chiefly PARP1 and PARP2, consume NAD+ to build poly(ADP-ribose) chains as part of the DNA damage response. CD38, an NADase expressed on immune and other cells, degrades NAD+ and its precursors and becomes more active in inflammatory contexts.

Because these enzymes destroy NAD+ rather than recycle it, the cell must continuously resynthesize it. The dominant route in mammals is the salvage pathway, in which nicotinamide is recycled back into nicotinamide mononucleotide by the enzyme NAMPT, and then into NAD+. NAMPT is widely considered the rate-limiting step. A parallel route, the Preiss-Handler pathway, starts from nicotinic acid, and de novo synthesis from tryptophan contributes a smaller share.

This architecture is the whole basis of the aging hypothesis. If DNA damage and inflammation rise with age, PARP and CD38 activity rises with them, NAD+ is consumed faster, sirtuin activity falls, and mitochondrial function degrades. It is a coherent story. Whether it is the correct story in living humans, and whether supplying more substrate reverses any part of it, is a separate empirical question that the next sections address.

This claim appears on virtually every commercial page about NAD+, usually with a confident percentage attached. The honest answer is more textured: the direction of the evidence favors a decline in several human tissues, but the magnitude, the universality and the causal meaning are all contested.

The most frequently cited human dataset comes from Massudi and colleagues, who analyzed human pelvic skin samples from 49 individuals ranging from newborns to age 77. They reported that DNA damage correlated strongly with age, that PARP activity increased with age in males, and that PARP activity was inversely correlated with tissue NAD+ levels. That is a single tissue, a modest sample, and a cross-sectional design, but it is real human data and it is consistent with the mechanistic model described above.

A 2022 Nature Aging study by Janssens and colleagues compared muscle metabolomes in young and older adults across different levels of muscle health and physical activity. Aging was characterized by lower NAD+ levels, but the finding came with an important qualifier: NAD+ abundance correlated with average daily step count and with mitochondrial and muscle function, and exercise-trained older individuals had NAD+ levels closer to those of younger participants. In other words, chronological age was not acting alone. Physical activity appeared to track with the outcome.

The most useful corrective is a 2022 review in Nutrients by Peluso, Damgaard, Mori and Treebak, which systematically examined studies reporting NAD+ levels with aging across yeast, C. elegans, rats, mice, monkeys and humans. Their conclusion was blunt: despite widespread claims of a general age-related NAD+ decline, the supporting evidence is limited and is often restricted to a single tissue or a single cell type. Animal data is considerably richer than human data, and extrapolating from a rodent liver to a human whole body is not a free move.

There is also a measurement problem that rarely appears in marketing copy. NAD+ is chemically unstable, its measured concentration depends heavily on sample handling and assay method, and whole blood levels do not necessarily reflect levels in muscle, liver, brain or skin. A finger-prick "NAD+ level" is not a validated biomarker of biological age. Treat any before-and-after number offered by a clinic with the same skepticism you would apply to any unvalidated test.

The marketing argument for injection is simple: oral NAD+ is destroyed in the gut, so bypassing the gut delivers the intact molecule. The first half of that statement is defensible. The second half skips over what happens once the molecule is in the bloodstream.

Extracellular NAD+ does not simply float to a cell and walk in. It is a substrate for ectoenzymes, including CD38 and various ectonucleotidases, which degrade it into nicotinamide mononucleotide, nicotinamide riboside and ultimately nicotinamide. Those smaller fragments are what cells take up and reassemble into intracellular NAD+ through the salvage pathway. Put plainly: even an intravenous infusion of NAD+ most likely delivers precursors to the cell, arriving by a longer and more expensive path than an oral precursor would.

The pilot pharmacokinetic work is consistent with this. In the 2019 study by Grant and colleagues, participants received 750 mg of NAD+ intravenously over six hours, an infusion rate of roughly 2 mg per minute. The investigators reported that no change in plasma NAD+ or in its metabolites (nicotinamide, methylnicotinamide, ADP-ribose and nicotinamide mononucleotide) was observed until after two hours. An infusion marketed as a rapid cellular recharge did not produce a rapid measurable change in the circulating NAD+ metabolome.

Here is how the main routes compare on the evidence that exists today:

None of this proves that injection is useless. It establishes that the burden of proof has not been met, and that the theoretical advantage of bypassing the gut is partly cancelled by extracellular degradation. If you are researching handling and administration practices more generally, our background articles on storage and reconstitution and on injection technique cover the mechanics without endorsing any specific regimen. This guide deliberately contains no dosing figures and no protocol.

Almost the entire randomized human evidence base for NAD+ augmentation concerns oral precursors, not injections. That is an important asymmetry, because commercial pages routinely cite precursor trials on pages selling injectable vials.

The first clinical pharmacokinetic study of nicotinamide riboside was published by Trammell and colleagues in Nature Communications in 2016. Single oral doses of 100 mg, 300 mg and 1,000 mg of NR produced dose-dependent increases in the blood NAD+ metabolome, establishing that NR is orally bioavailable and raises NAD+ related metabolites in humans.

Martens and colleagues then ran a 2 × 6-week randomized, double-blind, placebo-controlled crossover trial in 24 healthy middle-aged and older adults, using 500 mg of NR twice daily. Chronic supplementation was well tolerated and effectively stimulated NAD+ metabolism, which is precisely what the title of the paper claims and no more.

Elhassan and colleagues studied 12 aged men in a placebo-controlled, randomized, double-blind crossover trial, giving 1 g of NR per day for 21 days. Targeted metabolomics showed that NR elevated the muscle NAD+ metabolome, with increased nicotinic acid adenine dinucleotide and nicotinamide clearance products, and the authors also reported reductions in circulating inflammatory cytokines.

On the NMN side, Yoshino and colleagues published a 10-week randomized, placebo-controlled, double-blind trial in Science in 2021, enrolling 25 postmenopausal women with prediabetes who were overweight or obese, assigned to 250 mg per day of oral NMN or placebo. Insulin-stimulated glucose disposal measured by hyperinsulinemic-euglycemic clamp and skeletal muscle insulin signaling increased after NMN and did not change after placebo, and the authors reported no clinically relevant adverse changes in serum biochemistry, lipids or blood pressure.

Read together, the pattern is consistent and modest. Oral precursors reliably raise NAD+ related biomarkers in blood and in muscle, they have been generally well tolerated in short trials, and the downstream clinical effects are either small, restricted to specific populations, or not reproduced across studies. No published trial has demonstrated that raising NAD+ extends human lifespan or reverses aging. Anyone comparing options in this space may also find our overview of compounds studied for anti-aging useful for calibrating expectations across categories.

Very little, and it is worth stating that plainly before describing the two studies that exist.

The pilot study most often cited is Grant and colleagues, published in Frontiers in Aging Neuroscience in 2019. Eleven male participants aged 30 to 55 took part, with 8 in the test group and 3 receiving saline. The test group received 750 mg of NAD+ in normal saline over a 6 hour period, an infusion rate of approximately 2 mg per minute, equivalent to about 3 micromoles per minute. The study tracked plasma and urine NAD+ metabolites, and as noted above, no change in plasma NAD+ or in its metabolites was detected until after the two hour mark. This is a small, exploratory, pharmacokinetic study in healthy young-to-middle-aged men. It was never designed to test clinical benefit, and it does not.

More recently, Reyna and colleagues published a retrospective tolerability pilot study in Frontiers in Aging in 2026, reviewing electronic medical records from clients in a commercial wellness setting who received four consecutive days of 500 mg NAD+ IV or 500 mg NR IV, with 30 days of follow-up. Average infusion time was 96 minutes in the NAD+ group and 37 minutes in the NR group. Tolerability differed between groups: participants receiving NAD+ IV reported moderate to severe gastrointestinal symptoms, increased heart rate and chest pressure during infusions. A retrospective chart review in a commercial setting carries obvious limitations, including no randomization, no blinding and selection effects, but it is real-world human observation.

A narrative review published in Frontiers in Aging in September 2026, covering literature from January 2018 to March 2026, concluded that current evidence on IV NAD+ therapy remains preliminary and insufficient to support routine clinical or wellness use, and that robust conclusions about efficacy, durability, optimal dosing and long-term safety cannot currently be established.

For subcutaneous NAD+, the published controlled human evidence is thinner still. Small safety-oriented studies of injectable NAD+ and injectable NR have begun to appear, and registered trials of subcutaneous and intramuscular NR formulations exist, but these are preliminary safety investigations rather than efficacy trials, and there are no published long-term repeat-dose data. Any confident statement you encounter about what subcutaneous NAD+ does in humans over months is, at present, an extrapolation and not a finding.

The adverse effect profile of injected NAD+ is dominated by infusion-related symptoms rather than by delayed toxicity, at least in the short observation windows that have been published.

In the retrospective tolerability study by Reyna and colleagues, participants receiving NAD+ intravenously reported moderate to severe gastrointestinal symptoms, increased heart rate and chest pressure during the infusions, while the comparison group receiving intravenous NR did not report the same pattern. The 2026 narrative review lists nausea, cramping, flushing and chest discomfort among reported adverse effects and notes explicitly that long-term safety data are lacking.

These symptoms appear to be strongly rate-dependent. The Grant pilot study used a slow infusion, roughly 2 mg per minute across six hours, and the practical reason clinics extend NAD+ infusions over one to several hours is that faster administration is poorly tolerated. That relationship between speed and symptoms is a recurring observation in this literature, and it is one reason why a fast infusion is not a shortcut.

Flushing deserves a separate note because it is often misattributed. The intense, well-characterized flushing reaction associated with vitamin B3 is a property of nicotinic acid (niacin), mediated by prostaglandin release through the GPR109A receptor. Nicotinamide and nicotinamide riboside do not typically produce it. Flushing sensations described during NAD+ infusions are reported in the clinical literature but should not be assumed to share the same mechanism as classic niacin flush.

Beyond pharmacology, there are procedural risks that have nothing to do with the molecule itself. Injectable preparations obtained outside a regulated supply chain carry risks of contamination, endotoxin, incorrect concentration and non-sterile technique. Intravenous administration adds the risks of any cannulation procedure. There is also an unresolved theoretical question about chronic NAD+ precursor loading and methyl group consumption, since nicotinamide clearance proceeds through methylation, though this has not been established as a clinical problem in the short trials conducted so far.

Medical disclaimer. NAD+ is not approved as a therapy for aging, fatigue, addiction or cognitive decline. This section describes reported effects in published literature and is not medical advice. Anyone considering an infusion or injection should discuss it with a licensed physician who knows their medical history, particularly in the presence of cardiovascular disease, active malignancy, pregnancy or concurrent medication.

The regulatory picture splits sharply between the injectable coenzyme and the oral precursors, and it differs by jurisdiction.

Injectable NAD+ is not approved by the FDA or the EMA for any anti-aging, cognitive or metabolic indication. In the United States, NAD+ does not appear on the 21 CFR 216.23 list of bulk drug substances that may be used in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act, and the FDA has proposed that nicotinamide adenine dinucleotide not be included on that list. Clinics that offer NAD+ infusions are operating in a space that the agency has not endorsed, and product sold in vials to consumers is typically labeled for research use only.

NMN has had a turbulent regulatory history in the United States. In November 2022 the FDA determined that beta-nicotinamide mononucleotide was excluded from the definition of a dietary ingredient under the drug preclusion clause, on the basis that it had been authorized for investigation as a new drug before being marketed as a supplement. Following litigation, the agency reversed course and declared NMN lawful in dietary supplements in late 2025. Anyone reading older articles about NMN legality should check the date before relying on them.

NR has a clearer status. Nicotinamide riboside chloride was authorized in the European Union as a novel food under Regulation (EU) 2015/2283, with EFSA assessing its use in food supplements at a maximum of 300 mg per day, and a subsequent opinion addressing extension of use into additional food categories. Niacin and nicotinamide are established vitamins with defined reference intakes and long regulatory histories.

Three practical points follow. First, legal status varies by country and changes over time, so the position in your jurisdiction may not match what a US or EU page describes. Second, "research use only" labeling on a vial is a legal statement, not a quality certification. Third, third-party analytical certificates, sterility documentation and supplier transparency matter more for an injectable product than for a capsule.

If your question is a purchasing one rather than a scientific one, this guide is not the right page. We keep sourcing, supplier comparison and product considerations in a dedicated article: where to buy NAD+. That page handles regional availability and supplier routing, which this reference guide intentionally does not.

An honest reference guide should end by mapping the edge of the evidence rather than the center of it. Several questions remain open.

Whether raising circulating NAD+ raises it where it matters. Blood NAD+ metabolites respond reliably to oral precursors. Whether that translates into higher NAD+ inside aging neurons, cardiomyocytes or hepatocytes, in the specific subcellular compartments where sirtuins operate, is far less clear. Tissue-level measurement in living humans is difficult, and the few studies that have obtained muscle biopsies represent one tissue among many.

Whether the decline is cause or consequence. Lower NAD+ in aged tissue is compatible with two readings: NAD+ depletion drives dysfunction, or accumulated damage and inflammation consume NAD+ as a downstream effect. The Janssens finding that trained older adults maintained NAD+ levels closer to young participants is consistent with either interpretation. Restoring a marker does not necessarily restore the process that moved it.

Whether the route matters. No published study has compared intravenous NAD+, subcutaneous NAD+ and an oral precursor head to head, in the same participants, against meaningful clinical endpoints. Until such a comparison exists, claims that injection is superior to oral supplementation rest on a mechanistic argument that the extracellular degradation data partly undermines.

Dose, duration and who benefits. There is no established dose-response relationship for injected NAD+, no consensus on infusion duration, and no validated way to identify which individuals, if any, would benefit. Published trials have mostly enrolled small, homogeneous groups over weeks, not years. Long-term repeat-dose safety data for injectable NAD+ simply does not exist in the published literature.

Long-term safety signals. Sirtuins, PARPs and NAD+ metabolism intersect with DNA repair and cell proliferation. The theoretical questions this raises for individuals with a history of malignancy have not been resolved by adequately powered long-term studies in either direction, and the absence of reported harm in short trials is not the same as demonstrated long-term safety.

The appropriate posture is neither dismissal nor enthusiasm. NAD+ biology is well-established science. NAD+ injection as a wellness intervention is a commercial practice that has outpaced its evidence base. This article is for educational purposes only and is not medical advice. Consult a healthcare professional before considering any NAD+ product, by any route.